By: Natalie E. Gonzales
Peptides in Epilepsy: Unlocking New Therapeutic Pathways
Introduction
Epilepsy is a known neurological disorder that results in abnormal electrical activity, which can trigger seizures. Although medications can assist in managing seizures, some individuals still experience them despite being treated. Recent studies are investigating peptides, which are small protein-like substances in the brain, as a potentially effective method for treating epilepsy.
Peptides such as Neuropeptide Y (NPY) and galanin play a role in modulating brain function by reducing excitability, promoting neuronal health, and even facilitating the development of new brain cells. Researching these peptides is imperative, as it may lead to treatments that not only alleviate seizures but also safeguard the brain and enhance overall quality of life
How Peptides Work in the Brain
Peptides regulate brain activity by binding to specific receptor neurons. For example, NPY operates through Y2 and Y5 receptors to reduce the release of excitatory substances, such as glutamate, which can lead to seizures. Additionally, it supports neurogenesis, aiding the brain in its repair processes (Conttaneo et al., 2021). Galanin, another extensively researched peptide, primarily interacts with two receptors, GalR1 and GalR2. The activation of GalR1 helps to prevent seizures, whereas GalR2 may produce more varied effects depending on the specific region of the brain. Research in mice suggests that the absence of GalR1 leads to the development of spontaneous seizures and irregular brain activity, underscoring the importance of galanin for normal brain function (McColl et al., 2006; Lener, Sankar, & Mazarati, 2008). Ultimately, peptides engage with important chemicals such as GABA and glutamate to maintain a balance between the brain’s excitatory and inhibitory signals (Kovac & Walker, 2014).
Challenges in Developing Peptide Therapies
Although they hold great promise, using peptides for treatment poses significant challenges. Peptides are sensitive molecules that deteriorate rapidly within the body and struggle to cross the blood-brain barrier. Additionally, they must be directed to a specific area within the brain to work effectively. To address these challenges, researchers are developing synthetic versions of peptides with a longer lifespan and exploring gene therapy techniques that enable the brain to target specific brain regions (Cattaneo et al., 2021). These approaches aim to enhance the safety and effectiveness of peptide therapies.
Implications for Treatment
Peptide-based treatments may provide various advantages for individuals with epilepsy:
Improved seizure management by targeting the brain regions where seizures originate.
Reduced side effects compared to conventional medications.
Enhanced long-term brain health by repairing neural circuits and promoting neuron growth.
Researchers are investigating receptor-specific drugs, such as those that stimulate GalR1 or Y2/Y5 receptors, to optimize treatment and minimize undesirable effects.
By integrating peptides with other therapies, healthcare providers could enhance both seizure management and overall brain function.
Future Directions
Future studies are concentrating on several important areas:
Enhancing delivery and stability; developing peptides that can endure within the body and effectively reach the brain.
Gene therapy: employing viral vectors to enable specific regions of the brain to generate therapeutic peptides.
Receptor-specific medications: targeting GalR1, GalR2, or Y receptors for more accurate treatment
Network-based therapies – integrating peptides with other treatments to restore equilibrium in brain circuits
These innovations could lead to more effective, tailored epilepsy treatments with longer-lasting effects.
Conclusion
Peptides such as NPY and galanin present promising new opportunities for managing epilepsy. By soothing hyperactive neurons, promoting neuronal development, and targeting specific receptors, these peptides may help individuals reduce seizures and improve overall brain health. As research progresses, therapies based on peptides might play a vital role in the future treatment of epilepsy, providing hope for safer, more efficient, and sustainable solutions.
References
Cattaneo, S., Verlengia, G., Marino, P., Simonato, M., & Bettegazzi, B. (2021). NPY and Gene Therapy for Epilepsy: How, When,… and Y [Mini Review]. Frontiers in Molecular Neuroscience, Volume 13 – 2020. https://doi.org/10.3389/fnmol.2020.608001
Kovac, S., & Walker, M. C. (2014). Neuropeptides as targets for the development of anticonvulsant drugs. Neuropeptides, 48(6), 409–420. https://doi.org/10.1016/j.nepep.2014.08.001
Lerner, J. T., Sankar, R., & Mazarati, A. M. (2008). Galanin – 25 years with a multitalented neuropeptide: Galanin and epilepsy. Cellular and Molecular Life Sciences, 65(12), 1864–1871. https://doi.org/10.1007/s00018-008-8161-8
McColl, C., Jacoby, A. S., Shine, J., Iismaa, T. P., & Bekkers, J. (2006). Galanin receptor-1 knockout mice exhibit spontaneous epilepsy, abnormal EEGs and altered inhibition in the hippocampus. Neuropharmacology, 50(2), 209–218. https://doi.org/10.1016/j.neuropharm.2005.09.001
